NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Aspire Biopharma Holdings, Inc. (ASBP) Stock Analysis

Aspire Biopharma Holdings, Inc. (ASBP) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ASBP

$8.87

−$0.38 (−4.11%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ASBP with… →

ASBP Key Statistics

As of Sep 4, 2026
Trading
Open
$9.25
Previous Close
$9.25
Day's Range
8.80–9.50
52-Week Range
0.11–22.00
Volume
42.80K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.17
Valuation
Market Cap
$12.44M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
127.39
EPS (ttm)Profit attributable to each share over the last twelve months.
−6.65
Financials (FY)
Revenue (FY)
$6.20K
Net Income (FY)
−$24.48M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
1.40M
1-Year Return
−59.31%
Dividend and dates
Avg Volume
272.31K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ASBP Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+67.99%
2025−98.85%
2024+5.60%
2023+5.73%
2022 (partial year)+3.10%

As of September 4, 2026.

ASBP Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$6.20K−$24.48M−394725.1%
2024$0.00−$1.31M—
2023$0.00$4.46M—
2022$0.00−$597.12K—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$6.20K−$116.00−$19.35M−$24.48M−394725.1%
2024$0.00$0.00−$1.21M−$1.31M—
2023$0.00$0.00−$1.34M$4.46M—
2022$0.00$0.00−$596.49K−$597.12K—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ASBP Valuation vs Biotechnology Median

Median of 656 stocks
MetricASBPBiotechnology medianvs median
P/S ratio127.3915.268.3x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Aspire Biopharma Holdings, Inc. (ASBP) at $12.44M. The company sits in the Healthcare sector, in the Biotechnology industry.

The most recent close on file for ASBP is $8.87, dated September 4, 2026. That is −$0.38 (−4.11%) against the previous close. Over the past 52 weeks the price has ranged from $0.11 to $22.00. The latest close sits 7,963.64% above that 52-week low.

Financial Health

In fiscal 2025, Aspire Biopharma Holdings, Inc. reported revenue of $6.20K. The same year closed with a net loss of $24.48M. Profit margin runs at 0%. Trailing earnings per share are −6.65.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $6.20K in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 127.39. On price-to-sales that is 8.3 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The trailing one-year price return is −59.31%. Across 3 years the annualized return works out at −72.74%. The reported beta is 0.17. Annualized volatility over the trailing 4 years is 1,455.33%.

Growth & Income

No dividend is on file for ASBP.

Across the complete calendar years on file, 2023 returned +5.73% and 2025 returned −98.85%. Of the 3 complete calendar years on file, 2 finished higher. 2026 is still running; the price is +67.99% year to date.

Peer Comparison

Aspire Biopharma Holdings, Inc. (ASBP) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Aspire Biopharma Holdings, Inc. ASBP $12.44M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Aspire Biopharma Holdings, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Aspire Biopharma Holdings, Inc.

Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, such as melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement. The company was founded in 2021 and is headquartered in Estero, Florida.

Visit website →